Drug intelligence / Profile preview

NAV-004

Development stage: Preclinical
Lead developer: Navrogen
Modality: Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics

Overview

NAV-004 is a next-generation immunotoxin developed by Navrogen. It is a de-immunized immunotoxin specifically designed to target and kill regulatory T cells (T regs) via engagement of their CD25 receptors. By eliminating T regs, which produce immunosuppressive factors in the tumor microenvironment, NAV-004 aims to remove suppression on effector immune cells, thereby restoring and enhancing anti-tumor immune responses. The drug features an improved immunogenic profile compared to earlier immunotoxins[2].

Targets

IL2RA (Interleukin-2 receptor alpha subunit)

Beyond the preview

Go deeper on NAV-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NAV-004.

Explore the full profile